Lenvatinib for liver cancer in people with moderate liver damage
Treatments studied
Part of Cancer clinical trials.
This trial tests the drug lenvatinib (a pill that helps stop cancer growth) as a first treatment for people with liver cancer that cannot be surgically removed and who have moderate liver damage. It aims to see if lenvatinib can help control the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be 19 years or older.
- Diagnosed with liver cancer (hepatocellular carcinoma) that cannot be treated with surgery, transplant, or local therapies.
- Liver function must be moderately reduced (Child-Pugh class B7-B8).
- Must have at least one measurable tumor that can be tracked on scans.
- Must not have received whole-body cancer treatment (like pills or IV chemo) for this cancer before.
- Must be able to do daily activities with mild or moderate limitations (ECOG 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a combination of the drug lenvatinib, a liver treatment called TACE, and the immunotherapy drug camrelizumab can shrink advanced hepatocellular carcinoma enough to make surgery (or “conversion resection”) possible. It may help some people live longer by improving the chance that the cancer can be removed.
This trial tests a combination of a focused radiation beam (SBRT) plus a pill that helps stop tumor blood vessel growth (lenvatinib) and a procedure that blocks blood flow to the tumor (TACE) for people with advanced liver cancer that has not yet spread outside the liver. The goal is to see if this triple therapy can improve outcomes without prior treatment.
This trial tests a combination of a procedure that delivers chemotherapy directly to the liver tumor (called TACE) with an oral targeted therapy drug (lenvatinib) for people with liver cancer that cannot be removed with surgery. The goal is to see if this combination can shrink tumors more effectively than TACE alone.
This trial tests a new combination treatment before surgery for liver cancer. It aims to shrink tumors and reduce the chance of cancer coming back after surgery.
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
This trial tests a new drug (WGI-0301) combined with an existing liver cancer medicine (lenvatinib). It aims to see if the combination can help people with advanced liver cancer when other treatments haven't worked.
Hear when a new Advanced Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.